Lenvatinib Demonstrates Favorable Outcomes in Child-Pugh B Hepatocellular Carcinoma
Key Insights
Lenvatinib shows superior progression-free survival and objective response rate compared to sorafenib in unresectable HCC (search), according to the REFLECT trial.
Real-world data suggests lenvatinib may offer a more favorable overall survival compared to atezolizumab plus bevacizumab in Child-Pugh B HCC (search) patients.
Post-hoc analysis from REFLECT indicates that lenvatinib provides better overall survival than sorafenib in Child-Pugh B patients who initially had Child-Pugh A status.
Lenvatinib (Lenvima) has demonstrated promising outcomes in patients with Child-Pugh B hepatocellular carcinoma (search) (HCC (search)), a population often excluded from clinical trials. Recent data, including a post hoc analysis of the REFLECT trial and real-world studies, suggest that lenvatinib may offer survival benefits in this challenging patient group.
REFLECT Trial and Lenvatinib's Approval
The REFLECT trial, a phase 3, multicenter, noninferiority study, compared lenvatinib to sorafenib in patients with unresectable HCC (search). The trial's primary endpoint was noninferiority in overall survival (OS). While lenvatinib met the noninferiority endpoint (median OS 13.6 months vs 12.3 months for sorafenib, HR 0.92 [95% CI, 0.79-1.06]), it did not demonstrate superiority. However, lenvatinib showed significant improvements in progression-free survival (PFS) (7.4 months vs 3.7 months, HR 0.66; 95% CI, 0.57-0.77; P < .0001) and objective response rate (ORR) (24% vs 9%).
Real-World Evidence vs. Atezolizumab/Bevacizumab
In a real-world study comparing lenvatinib to atezolizumab (Tecentriq) plus bevacizumab (Avastin) in Child-Pugh B HCC (search) patients, lenvatinib showed a higher ORR (35% vs 18%). Although the progression-free survival (PFS) curves were similar, overall survival (OS) appeared more favorable with lenvatinib. This study, primarily based on data from France and Italy, included 217 patients, with 70% receiving lenvatinib and 30% receiving atezolizumab/bevacizumab.
GIDEON Registry Insights
The GIDEON registry, an observational study of over 5000 patients treated with sorafenib, provided insights into the impact of Child-Pugh scores on outcomes. The registry data revealed that patients with Child-Pugh C cirrhosis had a steeper mortality rate compared to those with Child-Pugh B or A. Notably, within the Child-Pugh B group, patients with a B7 score tended to have better outcomes than those with a B9 score, highlighting the heterogeneity within the Child-Pugh B classification.
Post Hoc Analysis of REFLECT
A post hoc analysis of the REFLECT trial examined patients who initially had Child-Pugh A status but progressed to Child-Pugh B at 8 weeks post-randomization. This analysis revealed that patients who remained Child-Pugh A had a higher ORR (42%) compared to those who progressed to Child-Pugh B (28.8%). However, lenvatinib consistently showed better PFS and OS compared to sorafenib in both Child-Pugh A and B subgroups.
Clinical Implications
These findings suggest that lenvatinib can be a valuable treatment option for Child-Pugh B HCC (search) patients, particularly those with less advanced liver disease (B7). While atezolizumab plus bevacizumab has emerged as a standard first-line treatment for advanced HCC, real-world data indicates lenvatinib may provide a survival advantage in Child-Pugh B patients. Further research is needed to validate these findings in randomized controlled trials.